New FDA-approved drug combo reduces prostate cancer death risk by 40 percent – The Times of India
A promising breakthrough in prostate cancer treatment shows new hope for men, especially if their cancer as resurfaced, following a primary surgery or radiation therapy. The recent findings from the third phase trial reveals a combination of two FDA-approved drugs, enzalutamide and leuprolide, significantly improves overall survival rates in patients with locally advanced prostate cancer,…